Therapeutic Usefulness of Postoperative Adjuvant Chemotherapy with Tegafur–Uracil (UFT) in Patients with Breast Cancer: Focus on the Results of Clinical Studies in Japan

Nakayama, Takahiro; Noguchi, Shinzaburo

doi:10.1634/theoncologist.2009-0255

Cited by 7 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hands, there are emerging studies suggesting that long-term continuous administration of tegafur-uracil for cancer control can inhibit the development of feeding blood vessels to tumors, thereby suppressing tumor growth and prolonging the duration of response. [41][42][43] Similar results with prolonged TTP and OS have been obtained with oral capecitabine alone. [44] Cisplatin plus capecitabine has also been shown to be a safe, convenient, and well-tolerated regimen, although hand-foot syndrome is an annoying and common side effect.…”

Section: Discussionsupporting

confidence: 65%

Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 65%

Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Regimens have evolved from simple bolus to sophisticated combination regimens, such as FOLFOX, FOLFIRI or FOLFIRINOX [16]. Furthermore, the oral F S1 [17], capecitabine and UFT [18] have been developed. Therefore, we analyzed the subgroup of trials evaluating doublets of G and F. Interestingly, the results of GF were largely similar to or even better by trend than those of GP.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials

Eckel

Schmid

2014

Chemotherapy

View full text Add to dashboard Cite

Background: In biliary tract cancer, gemcitabine platinum (GP) doublet palliative chemotherapy is the current standard treatment. The aim of this study was to analyze recent trials, even those small and nonrandomized, and identify superior new regimens. Methods: Trials published in English between January 2000 and January 2014 were analyzed, as well as ASCO abstracts from 2010 to 2013. Results: In total, 161 trials comprising 6,337 patients were analyzed. The pooled results of standard therapy GP (no fluoropyrimidine, F, or other drug) were as follows: the median response rate (RR), tumor control rate (TCR), time to tumor progression (TTP) and overall survival (OS) were 25.9 and 63.5%, and 5.3 and 9.5 months, respectively. GFP triplets as well as G-based chemotherapy plus targeted therapy were significantly superior to GP concerning tumor control (TCR, TTP) and OS, with no difference in RR. Conclusion: Triplet combinations of GFP as well as G-based chemotherapy with (predominantly EGFR) targeted therapy are most effective concerning tumor control and survival.

show abstract

“…Tegafur is often co-formulated with uracil or other active ingredients that enhance its bioavailability and reduce its toxicity [3][4][5]. It is metabolised to 5-FU in the body by cytochrome P450 2A6 and its terminal elimination half-life is 11 hours [6]. Despite its several benefits over 5-FU, orally administered tegafur needs to be taken twice or thrice daily and up to 20% of the pro-drug is excreted in urine un-metabolised.…”

Section: Introductionmentioning

confidence: 99%

Stoichiometric molecularly imprinted polymers for the recognition of anti-cancer pro-drug tegafur

Santos

Hall

Manesiotis

2016

Journal of Chromatography B

View full text Add to dashboard Cite

2 Highlights Molecularly Imprinted Polymers for anti-cancer pro-drug tegafur were prepared. Stoichiometric imprinting and a custom-made functional monomer were utilised. High selectivity for tegafur vs. other analytes was demonstrated. Clean extracts and recoveries of up to 96% from aqueous samples were achieved. 3 AbstractMolecularly Imprinted Polymers (MIPs) targeting tegafur, an anti-cancer 5-fluorouracil pro-drug, have been prepared by stoichiometric imprinting using 2,6-bis(acrylamido)pyridine ( The synthesised imprinted polymer was employed in solid-phase extraction of the pro-drug using an optimised protocol that included a simple wash with the porogen used in the preparation of the material.Tegafur recoveries of up to 96% were achieved from aqueous samples and 92% from urine samples spiked with the template and three competing analytes. The results demonstrate the potential of the prepared polymers in the pre-concentration of tegafur from biological samples, which could be an invaluable tool in the monitoring of patient compliance and drug uptake and excretion.

show abstract

Therapeutic Usefulness of Postoperative Adjuvant Chemotherapy with Tegafur–Uracil (UFT) in Patients with Breast Cancer: Focus on the Results of Clinical Studies in Japan

Abstract: ABSTRACT

Cited by 7 publications

References 33 publications

Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma

Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma

Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials

Stoichiometric molecularly imprinted polymers for the recognition of anti-cancer pro-drug tegafur

Contact Info

Product

Resources

About